Stock TLIS TALIS BIOMEDICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Talis Biomedical Corporation Stock

Equities

TLIS

US87424L2079

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
9.027 USD -1.35% Intraday chart for Talis Biomedical Corporation -1.88% +21.17%
May. 08 Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 02 North American Morning Briefing : Stocks Seen -2- DJ

Financials (USD)

Sales 2022 4.81M Sales 2023 2.13M Capitalization 13.57M
Net income 2022 -113M Net income 2023 -62M EV / Sales 2022 -17.6 x
Net cash position 2022 96.61M Net cash position 2023 57.06M EV / Sales 2023 -20.4 x
P/E ratio 2022
-0.11 x
P/E ratio 2023
-0.22 x
Employees 99
Yield 2022 *
-
Yield 2023
-
Free-Float 91.69%
More Fundamentals * Assessed data

Chart Talis Biomedical Corporation

Dynamic Chart

Latest news about Talis Biomedical Corporation

Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
North American Morning Briefing : Stocks Seen -2- DJ
Talis Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading DJ
Talis Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Talis Biomedical Announces Exploration of Strategic Alternatives CI
Talis Biomedical Corporation Announces Resignation of Melissa Gilliam from its Board of Directors, as Member of Nominating and Corporate Governance Committee and as Member and Co-Chairperson of Science, Technology and Clinical Affairs Committee CI
BTIG Adjusts Talis Biomedical's Price Target to $5 From $5.25, Keeps Sell Rating MT
Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Talis Biomedical Corporation, Q2 2023 Earnings Call, Aug 10, 2023
Talis Biomedical Corporation Announces Resignation of Andrew A. Lukowiak as President and Chief Scientific Officer CI
Talis Biomedical Corporation Announces New Data Supporting the Development of Its Planned CT/NG/TV and Vinal Infections Panels CI
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors CI
Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Talis Biomedical Corporation, Q1 2023 Earnings Call, May 11, 2023
More news

Latest transcript on Talis Biomedical Corporation

Logo Talis Biomedical Corporation
Talis Biomedical Corporation, Q2 2023 Earnings Call, Aug 10, 2023
More transcripts

Analyst Recommendations on Talis Biomedical Corporation

BTIG Adjusts Talis Biomedical's Price Target to $5 From $5.25, Keeps Sell Rating MT
BTIG Downgrades Talis Biomedical to Sell From Neutral; Price Target is $1 MT
BofA Securities Adjusts Talis Biomedical's Price Target to $1.50 from $3, Keeps Underperform Rating MT
BofA Securities Downgrades Talis Biomedical to Underperform From Neutral, Sets $3 Price Target MT
TALIS BIOMEDICAL : JPMorgan Downgrades Talis Biomedical to Underweight From Neutral, Cuts Price Target to $7 from $10 MT
More recommendations

Press releases Talis Biomedical Corporation

Talis: Q1 Earnings Snapshot AQ
Talis: Q3 Earnings Snapshot AQ
Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash AQ
Talis: Q2 Earnings Snapshot AQ
Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update AQ
More press releases

Quotes and Performance

1 day-1.35%
1 week-1.88%
Current month-1.88%
1 month-1.45%
3 months+9.42%
6 months+12.13%
Current year+21.17%
More quotes

Highs and lows

1 week
8.88
Extreme 8.88
9.53
1 month
8.67
Extreme 8.6657
9.59
Current year
7.01
Extreme 7.01
9.60
1 year
4.35
Extreme 4.35
9.60
3 years
4.35
Extreme 4.35
193.20
5 years
4.35
Extreme 4.35
508.50
10 years
4.35
Extreme 4.35
508.50
More quotes

Managers and Directors - Talis Biomedical Corporation

Managers TitleAgeSince
Robert Kelley CEO
 Chief Executive Officer 52 20-08-31
Rebecca Markovich DFI
 Director of Finance/CFO 51 21-12-31
Kim Popovits BRD
 Director/Board Member 65 20-07-30
Members of the board TitleAgeSince
Matthew Posard BRD
 Director/Board Member 56 16-02-29
Randal Scott BRD
 Director/Board Member 66 13-12-31
Kim Popovits BRD
 Director/Board Member 65 20-07-30
More insiders

Quotes

Date Price Change Volume
24-06-06 9.027 -1.35% 4,927
24-06-05 9.15 -1.45% 13,748
24-06-04 9.285 +0.38% 903
24-06-03 9.25 +0.54% 3,577
24-05-31 9.2 0.00% 1,354

Delayed Quote Nasdaq, June 06, 2024 at 04:30 pm EDT

More quotes

Company Profile

Talis Biomedical Corporation is a molecular diagnostic company. The Company is focused on advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.
Sector
Biotechnology & Medical Research
Calendar
2024-08-06 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TALIS BIOMEDICAL CORPORATION Stock Talis Biomedical Corporation
+21.17% 16.45M
MODERNA, INC. Stock Moderna, Inc.
+55.55% 59.28B
LONZA GROUP AG Stock Lonza Group AG
+43.23% 40.94B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-4.71% 40.17B
CELLTRION, INC. Stock Celltrion, Inc.
-5.56% 28.69B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.76% 26.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.00% 18.89B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.50% 12.46B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.16% 12.42B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.70% 12.26B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TLIS Stock